Paul Reider - Jan 3, 2025 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Stock symbol
CHRS
Transactions as of
Jan 3, 2025
Transactions value $
-$3,780
Form type
4
Date filed
1/7/2025, 08:50 PM
Previous filing
Dec 17, 2024
Next filing
Jan 22, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Tax liability -$3.78K -2.28K -2.55% $1.66 86.9K Jan 4, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +160K $0.00 160K Jan 3, 2025 Common Stock 160K $1.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.
F2 The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 3, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.